Premium Nahrungsergänzungsmittel | artgerecht

LDL-C Target Value: Levels, Risk Groups & Treatment

The LDL-C target value defines the desired maximum level of LDL cholesterol in the blood to reduce the risk of heart disease. It is set individually based on a patients cardiovascular risk profile.

Regular tips about health Regular tips about health

Things worth knowing about "LDL-C target value"

The LDL-C target value defines the desired maximum level of LDL cholesterol in the blood to reduce the risk of heart disease. It is set individually based on a patients cardiovascular risk profile.

What is the LDL-C Target Value?

The LDL-C target value refers to the recommended maximum level of LDL cholesterol (low-density lipoprotein cholesterol) in the blood. LDL cholesterol is a type of blood lipid that, when elevated, can damage blood vessel walls and contribute to the development of atherosclerosis (hardening of the arteries). The lower the LDL cholesterol level, the lower the risk of heart attack, stroke, and other cardiovascular diseases.

The target value is not the same for every patient. It is determined by the individual's cardiovascular risk profile and is tailored to their specific medical situation.

Why is the LDL-C Target Value Important?

Persistently elevated LDL cholesterol levels lead to the build-up of fatty plaques inside artery walls. These plaques can narrow or block blood vessels, potentially causing life-threatening events such as heart attack or stroke. Consistently achieving and maintaining the LDL-C target value is therefore a key goal in the prevention and treatment of cardiovascular disease.

Risk Groups and Their Target Values

The European guidelines of the ESC/EAS (European Society of Cardiology / European Atherosclerosis Society) classify patients into four risk categories and recommend corresponding LDL-C target values:

Very High Cardiovascular Risk

This group includes patients with established cardiovascular disease (e.g., after a heart attack or stroke), severe diabetes mellitus, chronic kidney disease, or a calculated 10-year risk of ≥ 10 % according to the SCORE2 model.

Target value: < 1.4 mmol/L (< 55 mg/dL)
Additionally: at least 50 % reduction from baseline

High Cardiovascular Risk

This includes patients with significantly elevated individual risk factors, moderate diabetes, or a 10-year risk of 5 % to < 10 %.

Target value: < 1.8 mmol/L (< 70 mg/dL)
Additionally: at least 50 % reduction from baseline

Moderate Cardiovascular Risk

Patients with a 10-year risk of 1 % to < 5 % according to SCORE2.

Target value: < 2.6 mmol/L (< 100 mg/dL)

Low Cardiovascular Risk

Patients with a 10-year risk below 1 % according to SCORE2.

Target value: < 3.0 mmol/L (< 116 mg/dL)

How to Achieve the LDL-C Target Value

Reaching the individual LDL-C target value is achieved through a combination of lifestyle changes and medical treatment:

Lifestyle Changes

Dietary adjustments: reducing saturated fats and trans fats, increasing fiber intake, vegetables, and healthy fats
Regular physical activity (at least 150 minutes of moderate exercise per week)
Weight management
Smoking cessation
Moderate alcohol consumption

Medical Treatment

Statins: First-line therapy; they inhibit cholesterol synthesis in the liver (e.g., atorvastatin, rosuvastatin)
Ezetimibe: Inhibits cholesterol absorption in the intestine; often combined with statins
PCSK9 inhibitors: Monoclonal antibodies (e.g., evolocumab, alirocumab) that powerfully reduce LDL cholesterol; used in very high-risk patients or those with statin intolerance
Inclisiran: An siRNA-based medication that inhibits PCSK9 production
Bempedoic acid: An alternative for patients who cannot tolerate statins

Monitoring and Follow-Up

After starting or changing a lipid-lowering therapy, LDL-C levels should be re-checked after 8–12 weeks to assess whether the target has been reached. Once values are stable, annual monitoring is recommended. Therapy is adjusted or escalated as needed until the individual target value is achieved.

References

Mach F et al. - 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2020; 41(1): 111-188.
Visseren FLJ et al. - 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021; 42(34): 3227-3337.
Grundy SM et al. - 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019; 73(24): e285-e350.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category